Discover how continuous manufacturing, advanced therapies, and global regulations are reshaping pharma production in this two-part series of Off Script: A Pharma Manufacturing Podcast.
This two-part series of Off Script: A Pharma Manufacturing Podcast features insights from CRB’s Horizons: Life Sciences 2025 report in a conversation with Peter Walters, Fellow of Advanced Therapies at CRB.
In Part One, Walters discusses how the pharmaceutical industry is advancing toward continuous manufacturing, including a key finding that 65% of large pharma companies are pursuing end-to-end continuous manufacturing to improve efficiency and product quality.
In Part Two, Walters expands the discussion to explore advanced therapies, emerging modalities, and the growing impact of standardization across global manufacturing networks. He also examines how tariffs, reshoring initiatives, and domestic investment strategies are influencing the future of pharma manufacturing.
Together, these episodes provide an in-depth look at the trends, technologies, and regulatory shifts shaping the next generation of pharmaceutical production.
Andy Lundin has more than 10 years of experience in business-to-business publishing producing digital content for audiences in the medical and automotive industries, among others. He currently works as Senior Editor for Pharma Manufacturing and is responsible for feature writing and production of the podcast.
His prior publications include MEDQOR, a real-time healthcare business intelligence platform, and Bobit Business Media. Andy graduated from California State University-Fullerton in 2014 with a B.A. in journalism. He lives in Long Beach, California.
